Profile
Andrea Grant served as the Chief Executive Officer, Executive Director & MD at Algorae Pharmaceuticals Ltd.
from 2012 to 2014.
Prior to that, she was the Chief Executive Officer at Diatranz Otsuka Ltd.
and the Managing Director at Galapagos Genomics NV.
Dr. Grant received her undergraduate and doctorate degrees from the University of Cambridge.
Former positions of Andrea Grant
| Companies | Position | End |
|---|---|---|
| ALGORAE PHARMACEUTICALS LIMITED | Chief Executive Officer | 2014-03-31 |
Galapagos Genomics NV
 Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Corporate Officer/Principal | 2008-05-01 |
Diatranz Otsuka Ltd.
 Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Chief Executive Officer | - |
Training of Andrea Grant
| University of Cambridge | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALGORAE PHARMACEUTICALS LIMITED | Health Technology |
| Private companies | 2 |
|---|---|
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
Diatranz Otsuka Ltd.
Diatranz Otsuka Ltd. Pharmaceuticals: MajorHealth Technology Diatranz Otsuka Ltd. manufactures pharmaceutical products. Its product, DIABECELL, is used to treat type1 diabetes. The company was founded on November 11, 2011 and is headquartered in Auckland, New Zealand. | Health Technology |
- Stock Market
- Insiders
- Andrea Grant